

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

In re Application of

Application Number

Filed

Group Art Unit

Examiner

Backstrom et al

08/736-267

Jan/24/96

Paper No. *# 39*

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ☒ (A) referred to in United States Patent Number 5952008 column _____
- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____
- ☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- ☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Anne Murphy

Signature

Anne MURPHY

Typed or printed name

6-27-01
Date

FOR PTO USE ONLY

Approved by: *gm*

(Initials)

Unit: *F-714*

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. The time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[54] PROCESSES FOR PREPARING COMPOSITIONS FOR INHALATION

[75] Inventors: Kjell Göran Erik Bäckström; Carl Magnus Olof Dahlbäck, both of Lund; Peter Edman, Bjärred; Ann Charlotte Birgit Johansson, Lund, all of Sweden

[73] Assignee: AB Astra, Sodertälje, Sweden

[*] Notice: This patent is subject to a terminal disclaimer.

[21] Appl. No.: 08/858,122

[22] Filed: May 19, 1997

Related U.S. Application Data

[60] Continuation of application No. 08/468,418, Jun. 6, 1995, abandoned, which is a division of application No. 08/265,237, Jun. 23, 1994, abandoned.

[30] Foreign Application Priority Data

Jun. 24, 1993 [SE] Sweden 9302198
Feb. 4, 1994 [SE] Sweden 9400371

[51] Int. Cl.⁶ A61K 9/14; A61K 9/72; A61K 38/16; A61K 47/12

[52] U.S. Cl. 424/499; 424/46; 424/489; 424/502; 424/85.2; 424/434; 514/2; 514/3; 514/951; 530/399

[58] Field of Search 424/46, 489, 499, 424/502, 85.2, 434; 514/2, 3, 8, 12, 54, 58, 800, 802, 805-890, 350, 359, 951; 530/303, 306, 307, 308, 311, 313, 315, 398, 399; 930/50

[56] References Cited

U.S. PATENT DOCUMENTS

3,014,844 12/1961 Thiel .
4,524,769 6/1985 Wetterlin 128/203.15
4,534,345 8/1985 Wetterlin 128/203.15
4,548,922 10/1985 Carey et al. 514/4
4,613,500 9/1986 Suzuki et al. 424/85.4
4,668,218 5/1987 Virtanen 604/58

4,690,952 9/1987 Kagatani et al. 514/11
4,746,508 5/1988 Carey et al. 424/88
4,788,221 11/1988 Kagatani et al. 514/12

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

43556/93 1/1994 Australia .
0 023 359 7/1980 European Pat. Off. .
0 055 041 12/1981 European Pat. Off. .
0 122 036 10/1984 European Pat. Off. .
0 200 383 4/1986 European Pat. Off. .
0 225 189 11/1986 European Pat. Off. .
0 272 097 6/1988 European Pat. Off. .
0 360 340 3/1990 European Pat. Off. .
0 455 463 11/1991 European Pat. Off. .

(List continued on next page.)

OTHER PUBLICATIONS

Olanoff et al., "Method to Enhance Intranasal Peptide Delivery", in "Controlled-Release Technology Pharmaceutical Applications", Lee et al., Ed., Published 1987 by The American Chemical Society, pp. 301-309.

Mishima et al., "Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats", J. Pharm. Sci., vol. 10, issued 1987, pp. 624-631.

(List continued on next page.)

Primary Examiner—Robert H. Harrison
Attorney, Agent, or Firm—Fish & Richardson P.C.

[57] ABSTRACT

A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.

49 Claims, 2 Drawing Sheets

